TEST:

PD-L1 IHC 73-10 pharmDx

For patients with TNBC at high risk of relapse who complete standard treatment with surgery and neoadjuvant/adjuvant chemotherapy, 1 year of adjuvant avelumab versus observation did not improve DFS. However, a descriptive analysis suggests a potential favorable impact on OS.

Clone 73 - 10 is a relatively suitable candidate for identifying patients with PD-L1 expression eligible for ICI therapy. It demonstrates high sensitivity in detecting PD-L1 (CD274) in HNSCC, offering immunological and prognostic insights.

Efficacy of avelumab for high-risk TNBC did not significantly differ by PD-L1 in the ITT, or by TILs and RCB in Stratum B. However, these biomarkers help identifying subgroups of patients at poorer prognosis deriving the greatest magnitude of benefit from this treatment.

The prognostic value of PD-L1 expression in both IC and TC differs between antibody clones, with 73-10 and SP263 being more reliable for prognostic information than 22C3 in resected CRC.

"The 73-10 clone assay's sensitivity ranged from 78.3% to 100% (TPS ≥1%), 100% (TPS ≥50%), and 77.4% to 93.5% (IPS ≥1%), while its specificity was 97.9% to 100% (TPS ≥1%), 99.5% to 99.8% (TPS ≥50%), and 97.9% to 100% (IPS ≥1%). This exploratory evaluation of LBS 73-10 monoclonal antibody on a large set of breast, colorectal, and hepatocellular carcinomas showed the assay's technical performance is comparable to the FDA-approved companion/complementary diagnostics PD-L1 detection assays."

PD-L1 CDx assays are critical for patient selection for anti PD1/PD-L1 checkpoint inhibitor treatment. Recently, it was reported that post translational modifications on PD-L1 can affect antibody detection thereby resulting in false negative diagnosis in a PD-L1 CDx assay.Using whole slide digital image analysis, quantitative mass spectroscopy and immunohistochemistry, we have developed and validated a multimodality workflow to quantitatively characterize total and glycosylated PD-L1 levels in FFPE tumor resections.We have investigated the impact of PD-L1 glycosylation on the detection sensitivity for two different PD-L1 antibody clones (73-10 and SP263) that are used in CDx assays and demonstrate that these clones are not affected by this post-translational modification.

P3; Longer median OS and PFS were observed with avelumab vs platinum-based doublet chemotherapy in advanced NSCLC, but differences in OS and PFS were not statistically significant, and the trial did not meet its primary objective.

Our analysis revealed high OPA between 73-10 and 22C3 as well as between 73-10 and 28-8. Further, our results of PPA and NPA might indicate that the results of 73-10 could be translated to those of 22C3 or those of 28-8. It was also indicated that the results of 22C3 could be translated to those of 73-10.

This study demonstrates that the location and conformation of binding sites, recognized by antibodies employed in PD-L1 diagnostic assays differ significantly and exhibit differing degrees of robustness. These findings should reinforce the need for vigilance when performing clinical testing with different PD-L1 IHC assays, particularly in the control of cold ischemia and the selection of fixation and decalcification conditions.

This pilot study demonstrates that most LACs are PDL1 negative, indicating that corresponding immunotherapy would be ineffective in these patients. The results are further supported by the Leica PD-L1 clone used in the study, because this clone 73-10 was reported to be more sensitive compared with the Dako PD-L1 22C3 pharmDx clone.

This pilot study demonstrates that most LACs are PDL1 negative, indicating that corresponding immunotherapy would be ineffective in these patients. The results are further supported by the Leica PD-L1 clone used in the study, because this clone 73-10 was reported to be more sensitive compared with the Dako PD-L1 22C3 pharmDx clone.

PD-L1 expression is common in GEP-NENs and increases with malignancy. Therefore, especially in high-grade GEP-NENs, targeting the PD-1/PD-L1 axis could be a promising additional therapeutic strategy.